INDIVIDUAL TEST 997-L

Beta amyloid ratio 42/40

Indication

In memory investigation, Alzheimer's disease

Method

Chemiluminescence 

Response

The result is reported as a ratio.

Reference interval: > 0.72 ( > 50 years of age).

Interpretation

Beta amyloid 40 is the most common variant of beta amyloid in CSF, while beta amyloid 42 predominates in senile plaques. Decreased ratio of Beta amyloid 42/40 is a strong marker of Alzheimer's disease and can be detected early in the disease progression, even before clinical dementia occurs.

References

  • Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019;11(1):34. PMID: 31010420
  • Dumurgier J, Schraen S, Gabelle A, et al. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther. 2015;7(1):30. PMID: 26034513

More information

Learn more about sampling.
> Read more

Download request forms

Neurology

Can't find what you're looking for? We are here to help

ENSKILD ANALYS 997-L

Beta amyloid kvot 42/40

Indikation

Vid minnesutredning, Alzheimer’s sjukdom

Metod

Kemiluminescens

Svar

Svaret rapporteras som en kvot.

Referensintervall: >0.72 ( >50 års ålder).

Tolkning

Beta amyloid 40 är den mest förekommande varianten av beta amyloid i likvor, men beta amyloid 42 dominerar i senila plaques. Sänkt kvot Beta amyloid 42/40 i likvor kan påvisas redan tidigt i sjukdomsförloppet av Alzheimers sjukdom, även innan klinisk demens föreligger och är av värde för att urskilja Alzheimer från andra former av demens. 

Referenser

  • Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019;11(1):34. PMID: 31010420
  • Dumurgier J, Schraen S, Gabelle A, et al. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther. 2015;7(1):30. PMID: 26034513

Mer information

Mer information om provtagning.
> Läs mer

Ladda ner remiss

Neurologi

Hittar du inte vad du söker? Vi kan hjälpa till